Heidi Colton

Heidi Colton serves as the Vice President of Nonclinical and Early Development at Geron Corporation since April 2025. Previously, Heidi held multiple positions at Chimerix, Inc. from April 2015 to April 2025, including Executive Director roles in Nonclinical Development Strategy and Translational Medicine, as well as Toxicology & Translational Medicine. Responsibilities included designing animal pharmacology studies and integrating nonclinical data to inform clinical dosing strategies. Prior experience includes roles at GSK, where Heidi served as Director of Investigative Toxicology and Clinical Safety Scientist, managing nonclinical safety strategies and conducting pharmacovigilance activities for oncology products. Heidi's career began at GSK as a Senior Scientific Investigator in Nonclinical Safety Assessment, contributing to initiatives like the Structural Cardiotoxicity Initiative and developing novel biomarker assays. Education includes a BS in Microbiology from Penn State University and further studies at North Carolina State University.